Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H Jr, Sayegh MH (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198:63–69

CAS  PubMed  PubMed Central  Google Scholar 

Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 42:e168

PubMed  PubMed Central  Google Scholar 

Buttenschon J, Svensmark B, Kyrval J (1995) Non-purulent arthritis in Danish slaughter pigs. I. A study of field cases. Zentralbl Veterinarmed A 42:633–641

CAS  PubMed  Google Scholar 

Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 14:569–579

PubMed  Google Scholar 

Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G (2014) COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol Ther Nucleic Acids 3:e214

CAS  PubMed  PubMed Central  Google Scholar 

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800

CAS  PubMed  Google Scholar 

Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Ichikawa Y, Kobayashi A, Shibahara T, Yanagawa Y, Higuchi H, Kato Y, Suzuki Y, Murata S, Ohashi K (2021) Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade. Immun Inflamm Dis. 

Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Minato E, Kobayashi A, Ando R, Sasaki N, Miyakoshi D, Ichii O, Kato Y, Suzuki Y, Murata S, Ohashi K (2020) PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade. PLoS ONE 15:e0234218

CAS  PubMed  PubMed Central  Google Scholar 

Goto S, Konnai S, Okagawa T, Nishimori A, Maekawa N, Gondaira S, Higuchi H, Koiwa M, Tajima M, Kohara J, Ogasawara S, Kato Y, Suzuki Y, Murata S, Ohashi K (2017) Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-gamma production via PD-1/PD-L1 blockade in bovine mycoplasmosis. Immun Inflamm Dis 5:355–363

CAS  PubMed  PubMed Central  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144

CAS  PubMed  PubMed Central  Google Scholar 

Henick BS, Herbst RS, Goldberg SB (2014) The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 18:1407–1420

CAS  PubMed  Google Scholar 

Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895

CAS  PubMed  PubMed Central  Google Scholar 

Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Maurer M, Wiendl H (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58:50–57

CAS  PubMed  Google Scholar 

Kula A, Dawidowicz M, Kiczmer P, Prawdzic Senkowska A, Swietochowska E (2020) The role of genetic polymorphism within PD-L1 gene in cancer. Review Exp Mol Pathol 116:104494

CAS  PubMed  Google Scholar 

Li H, Xu J, Bai Y, Zhang S, Cheng M, Jin J (2021) Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Invest New Drugs 39:860–870

CAS  PubMed  PubMed Central  Google Scholar 

Lippross S, Moeller B, Haas H, Tohidnezhad M, Steubesand N, Wruck CJ, Kurz B, Seekamp A, Pufe T, Varoga D (2011) Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum 63:3344–3353

CAS  PubMed  Google Scholar 

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391

CAS  PubMed  PubMed Central  Google Scholar 

Naito Y, Hino K, Bono H, Ui-Tei K (2015) CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 31:1120–1123

CAS  PubMed  Google Scholar 

Naujokat H, Sengebusch A, Loger K, Moller B, Acil Y, Wiltfang J (2021) Therapy of antigen-induced arthritis of the temporomandibular joint via platelet-rich plasma injections in domestic pigs. J Craniomaxillofac Surg 49:726–731

PubMed  Google Scholar 

Naujokat H, Sengebusch A, Moller B, Wieker H, Acil Y, Wiltfang J (2019) Antigen-induced arthritis of the temporomandibular joint via repeated injections of bovine serum albumin in domestic pigs. J Craniomaxillofac Surg 47:932–939

PubMed  Google Scholar 

Nguyen TV, Tanihara F, Do LTK, Sato Y, Taniguchi M, Takagi M, Van Nguyen T, Otoi T (2017) Chlorogenic acid supplementation during in vitro maturation improves maturation, fertilization and developmental competence of porcine oocytes. Reprod Domest Anim 52:969–975

CAS  PubMed  Google Scholar 

Niemann H, Kues WA (2003) Application of transgenesis in livestock for agriculture and biomedicine. Anim Reprod Sci 79:291–317

CAS  PubMed  Google Scholar 

Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151

CAS  PubMed  Google Scholar 

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322

ADS  CAS  PubMed  Google Scholar 

Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19:813–824

CAS  PubMed  Google Scholar 

Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14:779–782

CAS  PubMed  Google Scholar 

Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98:13866–13871

ADS  CAS  PubMed  PubMed Central  Google Scholar 

Onishi A, Iwamoto M, Akita T, Mikawa S, Takeda K, Awata T, Hanada H, Perry AC (2000) Pig cloning by microinjection of fetal fibroblast nuclei. Science 289:1188–1190

ADS  CAS  PubMed  Google Scholar 

Peng JM, Tian ZJ, Liu HG, An TQ, Zhou YJ, Wang Y, Li DY, Chen JZ, Yang YQ, Tong GZ (2010) Cloning and identification of porcine programmed death 1. Vet Immunol Immunopathol 136:157–162

CAS  PubMed  Google Scholar 

Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, Nesaei A, Hosseini SM (2018) PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics 70:73–86

CAS  PubMed  Google Scholar 

Sardar S, Andersson A (2016) Old and new therapeutics for rheumatoid arthritis: in vivo models and drug development. Immunopharmacol Immunotoxicol 38:2–13

CAS  PubMed  Google Scholar 

Shin JH, Park HB, Choi K (2016) Enhanced anti-tumor reactivity of cytotoxic T lymphocytes expressing PD-1 decoy. Immune Netw 16:134–139

PubMed  PubMed Central  Google Scholar 

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67:1471–1480

CAS  PubMed  PubMed Central  Google Scholar 

Tanihara F, Hirata M, Namula Z, Do LTK, Yoshimura N, Lin Q, Takebayashi K, Sakuma T, Yamamoto T, Otoi T (2023) Pigs with an INS point mutation derived from zygotes electroporated with CRISPR/Cas9 and ssODN. Front Cell Dev Biol 11:884340

PubMed  PubMed Central  Google Scholar 

Tanihara F, Hirata M, Nguyen NT, Le QA, Hirano T, Takemoto T, Nakai M, Fuchimoto DI, Otoi T (2018) Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation. PLoS ONE 13:e0206360

PubMed  PubMed Central  Google Scholar 

Tanihara F, Hirata M, Nguyen NT, Sawamoto O, Kikuchi T, Doi M, Otoi T (2020a) Efficient generation of GGTA1-deficient pigs by electroporation of the CRISPR/Cas9 system into in vitro-fertilized zygotes. BMC Biotechnol 20:40

CAS  PubMed  PubMed Central  Google Scholar 

Tanihara F, Hirata M, Nguyen NT, Sawamoto O, Kikuchi T, Otoi T (2021) One-step generation of multiple gene-edited pigs by electroporation of the CRISPR/Cas9 system into zygotes to reduce xenoantigen biosynthesis. Int J Mol Sci 22

Tanihara F, Hirata M, Thi Nguyen N, Le Anh Q, Hirano T, Otoi T (2020b) Generation of viable PDX1 gene-edited founder pigs as providers of nonmosaics. Mol Reprod Dev 87:471–481

CAS  PubMed  Google Scholar 

Tanihara F, Takemoto T, Kitagawa E, Rao S, Do LTK, Onishi A, Yamashita Y, Kosugi C, Suzuki H, Sembon S (2016) Somatic cell reprogramming-free generation of genetically modified pigs. Sci Adv 2:e1600803

ADS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J